Establishment Labs Holdings (ESTA) Announces Preliminary Results for Q4
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Establishment Labs Announces Preliminary Results for Fourth Quarter and Full Year 2019; Reports Record Revenue
January 28, 2020 4:06 PM ESTNEW YORK, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on Womens Health initially in the breast aesthetics and reconstruction market today announced preliminary financial results for the fourth quarter and full year 2019, with total revenue growth for the quarter of 43% to 49%.
2019 was another extraordinary year for Establishment Labs, and we ended the year on a strong note with our sixth consecutive quarter of record revenue performance, said Juan José Chacón-Quirós, Founder and CEO of Establishment Labs. We achieved increased... More
Establishment Labs Announces Proposed Public Offering of Common Shares
January 28, 2020 4:02 PM ESTNEW YORK, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (Nasdaq: ESTA) (the Company), a medical technology company focused on Womens Health initially in the breast aesthetics and reconstruction market today announced that it has commenced a public offering of approximately $55,000,000 of its common shares, to be sold by the Company in a registered public offering. The Company expects to grant the underwriters a 30-day option to purchase up to $8,250,000 of additional common shares. The offering is subject to market conditions, and there can be no assurance as to whether or when the... More
